Literature DB >> 1310444

Atrial and brain natriuretic peptides inhibit the endothelin-1 secretory response to angiotensin II in porcine aorta.

M Kohno1, K Yokokawa, T Horio, K Yasunari, K Murakawa, T Takeda.   

Abstract

We have recently shown that the porcine aorta releases immunoreactive endothelin-1 in a time-dependent way. Here, we examined the inhibition by atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) of endothelin-1 secretion after stimulation with angiotensin II (Ang II) by using porcine aorta. Ang II dose-dependently stimulated immunoreactive endothelin-1 secretion. Porcine ANP-(1-28) and porcine BNP-26 both inhibited such secretion in a dose-dependent way. The addition of a cyclic guanosine 5'-monophosphate (cGMP) analogue, 8-bromo-cGMP, reduced the immunoreactive endothelin-1 secretion after stimulation with Ang II. In cultured porcine endothelial cells the inhibition by porcine ANP-(1-28) and porcine BNP-26 of immunoreactive endothelin-1 secretion after stimulation with Ang II was paralleled by an increase in the cellular cGMP level. Rat ANP-(5-25) was weaker than porcine ANP-(1-28) in inhibiting immunoreactive endothelin-1 secretion and increasing cGMP in cultured cells. There was negative correlation between the percent decrease in immunoreactive endothelin-1 and the percent increase in cGMP. Neither porcine ANP-(1-28) nor BNP-26 affected the number or sensitivity of Ang II binding sites in cultured porcine endothelial cells. These results suggest that ANP and BNP inhibit endothelin-1 secretion after stimulation with Ang II, probably through a cGMP-dependent process.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1310444     DOI: 10.1161/01.res.70.2.241

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  10 in total

Review 1.  Therapeutic role of bosentan in hypertension: lessons from the model of perinephritic hypertension.

Authors:  J E Donckier
Journal:  Heart Fail Rev       Date:  2001-12       Impact factor: 4.214

Review 2.  The vascular endothelin system in hypertension--recent patents and discoveries.

Authors:  Meri M Hynynen; Raouf A Khalil
Journal:  Recent Pat Cardiovasc Drug Discov       Date:  2006-01

Review 3.  Regulation of blood pressure and salt homeostasis by endothelin.

Authors:  Donald E Kohan; Noreen F Rossi; Edward W Inscho; David M Pollock
Journal:  Physiol Rev       Date:  2011-01       Impact factor: 37.312

Review 4.  Modulators of the vascular endothelin receptor in blood pressure regulation and hypertension.

Authors:  Raouf A Khalil
Journal:  Curr Mol Pharmacol       Date:  2011-11       Impact factor: 3.339

Review 5.  Endothelins. A potential target for pharmacological intervention in diseases of the elderly.

Authors:  H Lévesque; N Moore; N Cailleux; V Richard; C Thuillez; H Courtois
Journal:  Drugs Aging       Date:  1994-03       Impact factor: 3.923

6.  Autocrine and paracrine effects of atrial natriuretic peptide gene transfer on vascular smooth muscle and endothelial cellular growth.

Authors:  R Morishita; G H Gibbons; R E Pratt; N Tomita; Y Kaneda; T Ogihara; V J Dzau
Journal:  J Clin Invest       Date:  1994-08       Impact factor: 14.808

7.  Long-term effects of B-type natriuretic peptide infusion after acute myocardial infarction in a rat model.

Authors:  Isaac George; Steve Xydas; Stefan Klotz; Ilan Hay; Chuck Ng; Jonathan Chang; Kai Xu; Zhihe Li; Andrew A Protter; Ed X Wu; Mehmet C Oz; Jie Wang
Journal:  J Cardiovasc Pharmacol       Date:  2010-01       Impact factor: 3.105

8.  Angiotensin converting enzyme inhibition modulates endogenous endothelin in chronic canine thoracic inferior vena caval constriction.

Authors:  A L Clavell; M T Mattingly; T L Stevens; A Nir; S Wright; L L Aarhus; D M Heublein; J C Burnett
Journal:  J Clin Invest       Date:  1996-03-01       Impact factor: 14.808

9.  Impact of hyperleptinemia during placental ischemia-induced hypertension in pregnant rats.

Authors:  Ana C Palei; Hunter L Martin; Barbara A Wilson; Christopher D Anderson; Joey P Granger; Frank T Spradley
Journal:  Am J Physiol Heart Circ Physiol       Date:  2021-03-12       Impact factor: 4.733

10.  Recombinant Brain Natriuretic Peptide for the Prevention of Contrast-Induced Nephropathy in Patients with Chronic Kidney Disease Undergoing Nonemergent Percutaneous Coronary Intervention or Coronary Angiography: A Randomized Controlled Trial.

Authors:  Jinming Liu; Yanan Xie; Fang He; Zihan Gao; Yuming Hao; Xiuguang Zu; Liang Chang; Yongjun Li
Journal:  Biomed Res Int       Date:  2016-02-02       Impact factor: 3.411

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.